Pfizer: Is This Stock Built to Last?
This video is part of our "Motley Fool Conversations" series, in which analyst John Reeves and advisor David Meier discuss topics across the investing world.
John and Dave take a closer look at Pfizer, one of the dominant companies in the Big Pharma space. Dave feels that the competitive landscape is pretty daunting for this company. But he also thinks it has a lot of natural advantages that may lead to success in the future. The video concludes with Dave's long-term outlook for this high-yielding Dow component.
Pfizer pays a pretty attractive yield of around 4.1 % right now. If you're interested in additional ideas on your quest for high-yielding stocks, The Motley Fool has compiled a special free report outlining our nine top, dependable, dividend-paying stocks. It's called "Secure Your Future With 9 Rock-Solid Dividend Stocks." You can access your copy today at no cost! Just click here to discover the winners we've picked.
At the time this article was published
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.